A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 2, 2012, Pages 1-26

  Jacobson, I M ^a,b   Pawlotsky, J M ^c   Afdhal, N H ^d,e   Dusheiko, G M ^f   Forns, X ^g   Jensen, D M ^h   Poordad, F ^i,j   Schulz, J ^k  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Clinical Care Options LLC   (United States)

more..

Author keywords

boceprevir; hepatitis C virus; telaprevir

Indexed keywords

ANTIHISTAMINIC AGENT; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; CALCINEURIN INHIBITOR; CYCLOSPORIN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ERYTHROPOIETIN; FOSAMPRENAVIR PLUS RITONAVIR; INTERLEUKIN 28B; LOPINAVIR PLUS RITONAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; RITONAVIR; STEROID; TACROLIMUS; TELAPREVIR; TENOFOVIR;

ANEMIA; ANORECTAL DISEASE; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC HEPATITIS; CLINICAL TRIAL (TOPIC); CONSENSUS; DATA ANALYSIS; DIZZINESS; DRESS SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSGEUSIA; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MIXED INFECTION; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STAGING; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; VIRUS HEPATITIS; VOMITING;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; OLIGOPEPTIDES; PRACTICE GUIDELINES AS TOPIC; PROLINE; PROTEASE INHIBITORS; VIREMIA;

EID: 84858432382     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01590.x     Document Type: Article

References (63)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
2. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567. (Pubitemid 41196755)
3. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academic Press, 2010.
4. Mitchell AE, Colvin HM, Palmer Beasley R,. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-733.
5. Verna EC, Brown Jr RS,. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-940. (Pubitemid 44895436)
6. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188.
7. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
8. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM,. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-1029.
9. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
10. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516.e1.
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
12. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
13. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
14. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-355.
15. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
16. Pearlman BL, Ehleben C, Saifee S,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694.
17. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460. (Pubitemid 44142452)
18. Buti M, Lurie Y, Zackharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52: 1201-1207.
19. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628.
20. Pearlman BL, Ehleben C,. Retreatment of chronic hepatitis C-genotype 1-infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin. Hepatology 2009; 50 (Suppl. 4): 686A.
21. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540.
22. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 1838-1846.
23. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
24. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
25. Kau A, Vermehren J, Sarrazin C,. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651.
26. Jacobson IM, Brown Jr RS, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46: 982-990. (Pubitemid 350144762)
27. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751-759.
28. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
29. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
30. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE Study. Hepatology 2010; 52 (Suppl. 1): 401A-402A.
31. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin. Hepatology 2010; 52 (Suppl. 1): 430A.
32. FDA Antiviral Drugs Advisory Committee Meeting. Boceprevir. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM254079.pdf. Accessed 3 August 2011.
33. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. J Hepatol 2011; 54 (Suppl. 1): S3.
34. Aronsohn A, Jensen D,. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology 2011; 53: 1789-1791.
35. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
36. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
37. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
38. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
39. Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Ailment Pharmacol Ther 2011; 33: 1162-1172.
40. Charles ED, Dustin JB,. Chemokine antagonism in chronic hepatitis C virus infection. J Clin Invest 2011; 121: 25-27.
41. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-Î-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53: 14-22.
42. Reddy KR, Bruno S, Rossaro L, et al. Predictors of sustained virologic response among treatment-naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR). J Hepatol 2011; 54 (Suppl. 1): S190.
43. Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial. J Hepatol 2011; 54 (Suppl. 1): S183-S184.
44. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
45. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54 (Suppl. 1): S542-S543.
46. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54 (Suppl. 1): S6-S7.
47. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54 (Suppl. 1): S6.
48. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433. (Pubitemid 41111423)
49. Zeuzem S, Vierling JM, Esteban R, et al. Predictors of sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus peginterferon alfa-2b/ribavirin. J Hepatol 2011; 54 (Suppl. 1): S198-S199.
50. Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011; 54 (Suppl. 1): S3-S4.
51. Victrelis [package insert]. Whitehouse Station, NJ: Merck, 2011.
52. Victrelis [boceprevir]. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002332/human-med-001464.jsp. Accessed 17 August 2011.
53. Incivek [package insert]. Cambridge, MA: Vertex, 2011.
54. Pawlotsky JM,. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751.
55. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 2011; 54 (Suppl. 1): S4.
56. Vierling JM, Kwo PY, Lawitz E, et al. Frequencies of resistance- associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology 2010; 52 (Suppl. 1): 702A-703A.
57. Zeuzem S, Barnard RJ, Howe JA, et al. Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin. J Hepatol 2011; 54 (Suppl. 1): S4-S5.
58. Sulkowski M, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2B/ribavirin with or without boceprevir is associated with higher SVR Rates: analysis of previously untreated and previous-treatment- failure patients. Gastroenterology 2011; 140 (Suppl. 1): S941-S942.
59. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous treatment-failure patients. J Hepatol 2011; 54 (Suppl. 1): S194-S195.
60. Poordad F, Sulkowski MS, Reddy R, et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimens in the ADVANCE and ILLUMINATE phase 3 studies. Gastroenterology 2011; 140 (Suppl. 1): S898-S899.
61. Sulkowski M, Dieterich D, Sherman K, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-alfa2a and RBV in HIV/HCV co-infected patients. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March, 2011; Boston, MA. Abstract 146LB. Available at: http://www.retroconference.org/2011/Abstracts/ 42467.htm. Accessed 6 October 2011.
62. Garg V, van Heeswijk R, Eun Lee J, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
63. Charlton M,. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents: a potentially lethal cocktail. Hepatology 2011; 54: 3-5.